- Education
- Research
- Transplant Oncology Infectious Diseases Program
Since its founding in 2012, our Transplant Oncology Infectious Diseases Clinical Research Unit (ID-CRU) has conducted over 60 studies, including both industry-sponsored and investigator-initiated clinical trials, epidemiologic studies, biospecimen collection studies, and chart review studies. The primary patient population that the ID-CRU serves includes the immunocompromised host, including renal and liver transplant patients, stem cell transplant patients, and those with other immunologic deficiencies. In addition, the ID-CRU has strong relationships with many services across Weill Cornell Medicine, due to the collaborative and cross-disciplinary nature of these studies. The ID-CRU continues to grow in staff and scope, and has performed as a top-enrolling site in many clinical trials. The ID-CRU was also a leader in COVID-19 studies at Weill Cornell Medicine, and has the capacity to provide regulatory and research staff support to other Divisions and Departments.
The ID-CRU has laboratory space equipped for basic molecular, microbiological, and immunologic studies. The laboratory contains freezers for study specimens (4°C, –20°C, and –80°C), an incubator, and a centrifuge. Staff offices are located on the Infectious Diseases floor at 1300 York Avenue, New York, NY, as well as in the hospital at 525 E 68th Street, New York, NY. The ID-CRU also has access to the Transplantation-Oncology Infectious Diseases Program Laboratory, which is Directed by Thomas Walsh, MD. This laboratory is a translational animal research lab that has multi-departmental collaborations with Departments of Medicine, Pediatrics, Microbiology and Immunology, and Neurosurgery.
The ID-CRU is directed by Michael J. Satlin, M.D. Dr. Satlin's research interests are in the epidemiology, diagnosis, and treatment of multidrug-resistant Gram-negative bacterial infections in immunocompromised hosts, and his research is supported by grants from NIAID and industry.
